Chemical meningitis related to intra-CSF liposomal cytarabine

CNS Oncol. 2017 Oct;6(4):261-267. doi: 10.2217/cns-2016-0046. Epub 2017 Oct 23.

Abstract

Therapeutic options of leptomeningeal metastases include intra-cerebrospinal fluid (CSF) chemotherapy. Among intra-CSF agents, liposomal cytarabine has advantages but can induce specific toxicities. A BRAF-V600E-mutated melanoma leptomeningeal metastases patient, treated by dabrafenib and liposomal cytarabine, presented after the first injection of liposomal cytarabine with hyperthermia and headaches. Despite sterile CSF/blood analyses, extended intravenous antibiotics were given and the second injection was delayed. The diagnosis of chemical meningitis was finally made. Dose reduction and appropriate symptomatic treatment permitted the administration of 15 injections of liposomal cytarabine combined with dabrafenib. A confirmation of the diagnosis of chemical meningitis is essential in order (1) not to delay intra-CSF or systemic chemotherapy or (2) to limit the administration of unnecessary but potentially toxic antibiotics.

Keywords: leptomeningeal metastasis; neoplastic meningitis; toxicity.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antimetabolites, Antineoplastic / administration & dosage
  • Antimetabolites, Antineoplastic / adverse effects*
  • Cytarabine / administration & dosage
  • Cytarabine / adverse effects*
  • Humans
  • Injections, Spinal
  • Male
  • Melanoma / drug therapy
  • Melanoma / secondary
  • Melanoma, Cutaneous Malignant
  • Meningeal Carcinomatosis / drug therapy*
  • Meningitis / chemically induced*
  • Middle Aged
  • Skin Neoplasms / drug therapy
  • Skin Neoplasms / secondary

Substances

  • Antimetabolites, Antineoplastic
  • Cytarabine